Seqens Seqens

X
[{"orgOrder":0,"company":"Mitsubishi Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mitsubishi Corporation Life Sciences Granted New US Patent for \"Composition Containing Glutathione as an Active Ingredient for Improvement or Prevention of Non-Alcoholic Fatty Liver\"","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"JAPAN","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals by Mitsubishi Corporation

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            USPTO has granted a patent to Mitsubishi Corporation Life Sciences for a method of improving nonalcoholic fatty liver disease in patients in need of treatment, comprising the administration of a composition containing glutathione as its active ingredient.

            Lead Product(s): Glutathione

            Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Opitac

            Highest Development Status: Undisclosed Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY